Ocular relapse of primary brain lymphoma in immunocompetent patient, treated with intrathecal rituximab

Clinical and Translational Oncology

Volumn 12, Issue 10, 2010, Pages 701-703

  Alonso, Constanza Maximiano ^a   Sánchez Ruiz, Antonio Carlos ^a   Sánchez De Ibargüen, Blanca Cantos ^a   García, Miriam Méndez ^a   Ronco, Isabel S ^a   Pulla, Mariano Provencio ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Intrathecal rituximab; Ocular relapse; Primary brain lymphoma

Indexed keywords

CD20 ANTIGEN; CONTRAST MEDIUM; FOLINIC ACID; INTERFERON REGULATORY FACTOR 4; METHOTREXATE; RITUXIMAB;

ADULT; ALKALINIZATION; ANTIGEN EXPRESSION; ARTICLE; BRAIN BIOPSY; BRAIN LYMPHOMA; BREAST CANCER; CANCER RELAPSE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIZZINESS; DRUG RESPONSE; EYE CANCER; HUMAN; HUMAN TISSUE; IMMUNOCOMPROMISED PATIENT; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPHTHALMOSCOPY; RADIATION DOSE FRACTIONATION; VOMITING; WEAKNESS;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; EYE NEOPLASMS; HUMANS; INJECTIONS, SPINAL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED;

EID: 78649684433     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-010-0580-y     Document Type: Article

References (18)

1. L.J. Swinnen 2009 Primary central nervous system lymphoma: recent progress, many remaining questions Curr Opin Oncol 5 393 396 10.1097/CCO.0b013e32832f3cb7
2. M. Sierra del Rio A. Rousseau C. Soussain, et al. 2009 Primary CNS lymphoma in immunocompetent patients Oncologist 14 526 539 1:CAS:528: DC%2BD1MXnvVOltr4%3D 10.1634/theoncologist.2008-0236 19433528
3. K. Hoang-Xuan S. Camilleri-Broët C. Soussain 2004 Recent advances in primary CNS lymphoma Curr Opin Oncol 6 601 606 10.1097/01.cco.0000142927.88773. 7e (Pubitemid 39482981)
4. M. Montesinos-Rongen R. Siebert M. Deckert 2009 Primary lymphoma of the central nervous system: just DLBCL or not? Blood 113 7 10 1:CAS:528: DC%2BD1MXmtFSksg%3D%3D 10.1182/blood-2008-04-149005 18802010
5. J.E. Uhm K.H. Kim S.Y. Yi, et al. 2009 A retrospective study to compare two methotrexate-based regimens for primary central nervous system lymphoma Leuk Lymphoma 50 1110 1118 1:CAS:528:DC%2BD1MXnvVOnsLw%3D 10.1080/10428190902964776 19557631
6. M. Ekenel F.M. Iwamoto L.S. Ben-Porat, et al. 2008 Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy 113 1025 1031 1:CAS:528:DC%2BD1cXhtFSlurrP
7. A.D. Voloschin R. Betensky P.Y. Wen, et al. 2008 Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma J Neurooncol 86 211 215 1:CAS:528:DC%2BD1cXisFCmtbg%3D 10.1007/s11060-007-9464-6 17896078 (Pubitemid 350263420)
8. P.G. Morris L.E. Abrey 2009 Therapeutic challenges in primary CNS lymphoma Lancet Neurol 8 581 592 1:CAS:528:DC%2BD1MXmvVyjurs%3D 10.1016/S1474-4422(09)70091-2 19446277
9. A.P. Algazi C. Kadoch J.L. Rubenstein 2009 Biology and treatment of primary central nervous system lymphoma Neurotherapeutics 3 587 597 10.1016/j.nurt.2009.04.013
10. C. Soussain K. Hoang-Xuan L. Taillandier, et al. 2008 Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire J Clin Oncol 26 2512 2518 10.1200/JCO.2007.13.5533 18413641
11. J.L. Rubenstein D. Combs J. Rosenberg, et al. 2003 Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment Blood 101 466 468 1:CAS:528:DC%2BD3sXkvVWksw%3D%3D 10.1182/blood-2002-06-1636 12393404 (Pubitemid 36077565)
12. K. Jahnke N.D. Doolittle L.L. Muldoon E.A. Neuwelt 2006 Implications of the blood-brain barrier in primary central nervous system lymphoma Neurosurg Focus 21 E11 10.3171/foc.2006.21.5.12 17134113
13. S. Stapleton S. Blaney 2006 New agents for intrathecal administration Cancer Invest 5 528 534 10.1080/07357900600815166 (Pubitemid 44576407)
14. J.C. Jaime-Pérez L.N. Rodríguez-Romo O. González-Llano, et al. 2009 Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy Br J Haematol 144 794 795 10.1111/j.1365-2141.2008.07497.x 19036096
15. J.L. Rubenstein J. Fridlyand L. Abrey, et al. 2007 Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma J Clin Oncol 25 1350 1356 1:CAS:528:DC%2BD2sXlt1Ghurw%3D 10.1200/JCO.2006.09.7311 17312328 (Pubitemid 46706881)
16. H. Schulz H. Pels I. Schmidt-Wolf, et al. 2004 Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab Haematologica 89 753 754 1:CAS:528:DC%2BD2cXmtlGrtL4%3D 15194546
17. S. Itty J.S. Pulido 2009 Rituximab for intraocular lymphoma Retina 29 129 132 10.1097/IAE.0b013e318192f574 19202422
18. G. Antonini M.C. Cox E. Montefusco, et al. 2007 Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma J Neurooncol 81 197 199 10.1007/s11060-006-9217-y 16937012 (Pubitemid 44963979)